Published in Nat Genet on October 28, 2002
Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science (2010) 6.04
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol (2010) 3.48
Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol (2009) 2.79
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. Genes Dev (2010) 2.31
Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol (2006) 2.01
Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol (2006) 2.00
Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med (2005) 2.00
The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol (2012) 1.90
Malignant pirates of the immune system. Nat Immunol (2011) 1.87
Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol Cell Biol (2006) 1.85
An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol (2007) 1.69
Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood (2009) 1.64
Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med (2008) 1.56
Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol (2010) 1.55
Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol (2005) 1.52
Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47
The genomic landscapes of inflammation. Genes Dev (2011) 1.45
CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol (2008) 1.41
Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol (2013) 1.30
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood (2011) 1.22
Regulation of the rapsyn promoter by kaiso and delta-catenin. Mol Cell Biol (2004) 1.22
Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood (2006) 1.21
Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription. Biochem J (2007) 1.19
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood (2010) 1.18
The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol (2013) 1.12
Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol (2010) 1.11
Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol (2011) 1.11
CPLA 1.0: an integrated database of protein lysine acetylation. Nucleic Acids Res (2010) 1.08
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene (2014) 1.05
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci U S A (2012) 1.05
Epigenetic control of immunity. Cold Spring Harb Perspect Biol (2014) 1.05
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs (2010) 1.05
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med (2015) 1.04
Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res (2010) 1.02
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) (2010) 1.02
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leuk Lymphoma (2008) 1.00
Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer (2013) 0.97
Rac1 signaling modulates BCL-6-mediated repression of gene transcription. Mol Cell Biol (2009) 0.96
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res (2014) 0.94
Computational and functional analysis of growth hormone (GH)-regulated genes identifies the transcriptional repressor B-cell lymphoma 6 (Bc16) as a participant in GH-regulated transcription. Endocrinology (2009) 0.94
New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Curr Opin Immunol (2013) 0.91
SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress. Genes Cancer (2013) 0.89
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol (2010) 0.88
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.88
Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw (2012) 0.87
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica (2009) 0.87
The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. Cell Rep (2014) 0.87
Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem (2013) 0.86
Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol (2016) 0.85
Mi-2/NuRD chromatin remodeling complexes regulate B and T-lymphocyte development and function. Immunol Rev (2014) 0.85
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep (2012) 0.83
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics (2015) 0.83
Fas apoptosis inhibitory molecule enhances CD40 signaling in B cells and augments the plasma cell compartment. J Immunol (2009) 0.83
SIRT1 links CIITA deacetylation to MHC II activation. Nucleic Acids Res (2011) 0.82
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal (2014) 0.82
The zinc finger transcription factor ZXDC activates CCL2 gene expression by opposing BCL6-mediated repression. Mol Immunol (2013) 0.82
Roles of repressive epigenetic machinery in lineage decision of T cells. Immunology (2013) 0.81
Bcl6a function is required during optic cup formation to prevent p53-dependent apoptosis and colobomata. Hum Mol Genet (2013) 0.81
EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells. J Virol (2006) 0.81
Acetylation of myocardin is required for the activation of cardiac and smooth muscle genes. J Biol Chem (2012) 0.80
Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis. Proc Natl Acad Sci U S A (2012) 0.80
The Crebbp Acetyltransferase is a Haploinsufficient Tumor Suppressor in B Cell Lymphoma. Cancer Discov (2017) 0.80
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood (2016) 0.80
Is glioblastoma an epigenetic malignancy? Cancers (Basel) (2013) 0.79
Looking for putative functions of the Leishmania cytosolic SIR2 deacetylase. Parasitol Res (2006) 0.79
Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions. Clin Cancer Res (2012) 0.79
Bcl6 middle domain repressor function is required for T follicular helper cell differentiation and utilizes the corepressor MTA3. Proc Natl Acad Sci U S A (2015) 0.79
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer. PLoS Genet (2016) 0.79
Alternative splicing generates a short BCL6 (BCL6S) isoform encoding a compact repressor. Biochem Biophys Res Commun (2008) 0.78
A novel mechanism involving coordinated regulation of nuclear levels and acetylation of NF-YA and Bcl6 activates RGS4 transcription. J Biol Chem (2010) 0.78
Strategies to modulate heritable epigenetic defects in cellular machinery: lessons from nature. Pharmaceuticals (Basel) (2012) 0.78
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica (2016) 0.77
Vorinostat-An Overview. Indian J Dermatol (2015) 0.77
Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors. Curr Top Med Chem (2016) 0.77
Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer. Biomol Ther (Seoul) (2012) 0.77
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Scientifica (Cairo) (2016) 0.76
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res (2015) 0.76
Reciprocal occupancy of BCL6 and STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and promoter-specific roles of p300 and HDAC3. Mol Cell Endocrinol (2014) 0.76
Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. Epigenetics Chromatin (2015) 0.75
Regulation of hematopoietic development by ZBTB transcription factors. Int J Hematol (2016) 0.75
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2017) 0.75
Identification of zinc finger protein Bcl6 as a novel regulator of early adipose commitment. Open Biol (2016) 0.75
AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs. PLoS One (2015) 0.75
Dynamic expression of BCL6 in murine conventional dendritic cells during in vivo development and activation. PLoS One (2014) 0.75
Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma. Trends Genet (2015) 0.75
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Invest New Drugs (2015) 0.75
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harb Mol Case Stud (2017) 0.75
An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog (2017) 0.75
Reverse engineering of regulatory networks in human B cells. Nat Genet (2005) 13.16
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Modes of p53 regulation. Cell (2009) 9.31
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 7.71
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol (2006) 5.70
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell (2006) 5.64
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol (2003) 5.46
SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell (2007) 5.30
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 5.23
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature (2004) 5.06
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab (2008) 4.89
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell (2005) 4.60
Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 4.55
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell (2002) 4.33
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab (2005) 4.14
A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell (2004) 4.05
A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell (2007) 3.81
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol (2005) 3.75
Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A (2003) 3.45
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem (2002) 3.37
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
Non-invasive prenatal measurement of the fetal genome. Nature (2012) 3.11
Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics (2007) 3.09
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Parc: a cytoplasmic anchor for p53. Cell (2003) 3.06
A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol (2008) 2.99
A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol (2010) 2.92
Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol (2006) 2.85
Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol (2009) 2.79
AID is required for germinal center-derived lymphomagenesis. Nat Genet (2007) 2.79
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 2.72
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell (2012) 2.46
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood (2012) 2.30
Nearly finished genomes produced using gel microdroplet culturing reveal substantial intraspecies genomic diversity within the human microbiome. Genome Res (2013) 2.29
PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc Natl Acad Sci U S A (2005) 2.13
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood (2002) 2.13
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol (2010) 2.03
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell (2011) 2.01
Microfluidics for flow cytometric analysis of cells and particles. Physiol Meas (2005) 2.00
Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood (2003) 1.93
Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem (2003) 1.92
Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood (2002) 1.91
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol (2012) 1.90
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood (2012) 1.88
Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol Cell (2011) 1.87
Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev (2003) 1.84
Identification of the human mature B cell miRNome. Immunity (2009) 1.82
SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest (2012) 1.82
Tracking CD40 signaling during germinal center development. Blood (2004) 1.81
Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev (2012) 1.78
SnapShot: p53 posttranslational modifications. Cell (2008) 1.75
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood (2003) 1.74
Expression of the AID protein in normal and neoplastic B cells. Blood (2004) 1.73
Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell (2009) 1.72
Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood (2011) 1.72
Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature (2010) 1.71
Improving genome assemblies by sequencing PCR products with PacBio. Biotechniques (2012) 1.70
Computer-controlled microcirculatory support system for endothelial cell culture and shearing. Anal Chem (2005) 1.70
Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression. Mol Cell (2013) 1.67
The impact of acetylation and deacetylation on the p53 pathway. Protein Cell (2011) 1.66
tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.66
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood (2009) 1.64
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest (2003) 1.63
BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.62
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood (2005) 1.59
Quantitative acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol Cell Proteomics (2012) 1.54
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood (2011) 1.53
α-adducin Gly460Trp polymorphism and essential hypertension risk in Chinese: a meta-analysis. Hypertens Res (2011) 1.51
p53 regulation by ubiquitin. FEBS Lett (2011) 1.51
Translation of ASH1 mRNA is repressed by Puf6p-Fun12p/eIF5B interaction and released by CK2 phosphorylation. Genes Dev (2008) 1.50